The company expects net product revenues from sales of zynlonta to be approximately $15.8M for the third quarter ended September 30, with cash and cash equivalents totaling $234.7M as of September 30, 2025. Giving effect to the estimated net proceeds from the PIPE financing of approximately $57.6M, the company would have had approximately $292.3M of cash and cash equivalents as of that date.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT: